Clinical Trial

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory acute myeloid leukemia (AML). In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with modifications: 1) reduced dose of CLAGE; 2) Reduced intensity conditioning (RIC) regimen as fludarabine, busulfan and melphalan (MBF) or total marrow irradiation (TMI); 3) Venetoclax was added to the chemotherapy and conditioning regimen.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-22; most recent amendment 2025-02-14.
Trial Details
NCT Number NCT05870995
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Refractory Leukemia
Enrollment 100 participants
Start Date 2023-02-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-18